Getting to the Right Relationship Between Doctors and Drug Companies
There is a way to cultivate, not demonize, collaboration between physicians and pharma. More »
Advertisement
David A. Shaywitz, MD, PhD, is a new-product-development strategist at a biopharmaceutical company in San Francisco, co-founder of the Center for Assessment Technology and Continuous Health at Massachusetts General Hospital and MIT, and an adjunct scholar at the American Enterprise Institute. More
Trained as a physician-scientist and management consultant, Dr. Shaywitz has experience in clinical drug development and strategic and commercial planning. Dr. Shaywitz is co-founder of the Center for Assessment Technology and Continuous Health (CATCH), a Boston-based initiative to use improved real-world measurement to improve care and drive science. He also is co-founder of the Harvard PASTEUR program, a translational research initiative at Harvard Medical School, and a founding advisor of Sage Bionetworks, a non-for-profit medical research initiative focused on open innovation. He works at a biopharmaceutical company in San Francisco; the views expressed in his postings are his own and do not represent the views of his employer. Dr. Shaywitz is an adjunct scholar at the American Enterprise Institute. His personal website is: http://davidshaywitz.wordpress.com.
There is a way to cultivate, not demonize, collaboration between physicians and pharma. More »
Question the intuitive "best" practice; never assume we know enough. More »
The human connection is threatened by a reductive focus on data collection, algorithms, and information transaction. More »
Physicians won't become obsolete any time soon, but the comprehensive integration of everything we know about well-being could revolutionize medical care. More »
America must recommit to U.S. medical culture's first principles. More »
The Supreme Court's recent decision on health care exposes an age-old debate: focus resources on the treatments we have, or set our sights on pricey research for future cures? More »
Will Silicon Valley lead health care's next revolution -- or miss it? More »
Soon, you won't only be responsible for managing your disease -- you may also be expected to help find your own cure. More »
Successfully translating scientific discoveries requires a primal sense of urgency, which some disease foundations seem to have, and many big pharmas appear to need. More »
The entrepreneur and process methods -- two ways of dealing with the problems created by a business segregated into extreme phenotypes More »
In the development of drugs, it's too difficult to change things on the fly, and to rapidly pivot in response to an appreciation of customer need More »
At large, established companies, doing old things more efficiently becomes more important than doing new things. That's the problem. More »
The challenge for medicine is not only to utilize patient-focused technologies, but also to recognize the unquantifiable benefit that comes from a reassuring nod, a hand on the shoulder More »
The kind of design thinking championed by Steve Jobs -- human-centered, iterative, and practical -- can fix more than just our gadgets More »
